BRCA1 and ovarian carcinoma: In the scenario of Brazilian ovarian cancer patients, for whom BRCA1/BRCA2 mutation frequency is 20%, performing genetic testing and adopting prophylactic measures for family members was considered a cost-effective measure (33).